[1] Soupene E, Kuypers F A. Mammalian long-chain acyl-CoA synthetases[J]. Exp Biol Med (Maywood), 2008, 233(5):507-521.
[2] Yan S, Yang X F, Liu H L, et al. Long-chain acyl-CoA synthetase in fatty acid metabolism involved in liver and other diseases: an update[J]. World J Gastroenterol, 2015, 21(12):3492-3498.
[3] Kuwata H, Hara S. Role of acyl-CoA synthetase ACSL4 in arachidonic acid metabolism[J]. Prostaglandins Other Lipid Mediat, 2019, 144:106363.
[4] Doll S, Proneth B, Tyurina Y Y, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13(1):91-98.
[5] Golej D L, Askari B, Kramer F, et al. Long-chain acyl-CoA synthetase 4 modulates prostaglandin E2 release from human arterial smooth muscle cells[J]. J Lipid Res, 2011, 52(4):782-793.
[6] Küch E M, Vellaramkalayil R, Zhang I, et al. Differentially localized acyl-CoA synthetase 4 isoenzymes mediate the metabolic channeling of fatty acids towards phosphatidylinositol[J]. Biochim Biophys Acta, 2014, 1841(2):227-239.
[7] Kuwata H, Yoshimura M, Sasaki Y, et al. Role of long-chain acyl-coenzyme A synthetases in the regulation of arachidonic acid metabolism in interleukin 1β-stimulated rat fibroblasts[J]. Biochim Biophys Acta, 2014, 1841(1):44-53.
[8] Kan C F, Singh A B, Stafforini D M, et al. Arachidonic acid downregulates acyl-CoA synthetase 4 expression by promoting its ubiquitination and proteasomal degradation[J]. J Lipid Res, 2014, 55(8):1657-1667.
[9] Killion E A, Reeves A R, El Azzouny M A, et al. A role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced phospholipid remodeling and obesity-associated adipocyte dysfunction[J]. Mol Metab, 2018, 9:43-56.
[10] Ren H, Zhang H, Hua Z, et al. ACSL4 directs intramuscular adipogenesis and fatty acid composition in pigs[J]. Animals (Basel), 2022, 12(1):119.
[11] Ansari I H, Longacre M J, Stoker S W, et al. Characterization of Acyl-CoA synthetase isoforms in pancreatic beta cells: gene silencing shows participation of ACSL3 and ACSL4 in insulin secretion[J]. Archives of Biochemistry and Biophysics, 2017, 618:32-43.
[12] Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1):202-209.
[13] Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7):908-922.
[14] Stepanova M, Hossain N, Afendy A, et al. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease[J]. Obes Surg,2010, 20(5):640-650.
[15] Westerbacka J, Kolak M, Kiviluoto T, et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects[J]. Diabetes, 2007, 56(11):2759-2765.
[16] Tang J, Wang L, Shi M, et al. Study on the mechanism of shuganzhi tablet against nonalcoholic fatty liver disease and lipid regulation effects of its main substances in vitro[J]. J Ethnopharmacol, 2023, 316:116780.
[17] Georgiadou A, Dunican C, Soro-Barrio P, et al. Comparative transcriptomic analysis reveals an association of gibel carp fatty liver with ferroptosis pathway[J]. BMC Genomics, 2021, 22(1):328.
[18] Kan C F, Singh A B, Dong B, et al. PPARδ activation induces hepatic long-chain acyl-CoA synthetase 4 expression in vivo and in vitro[J]. Biochim Biophys Acta, 2015, 1851(5):577-587.
[19] Sen P, Kan C F K, Singh A B, et al. Identification of p115 as a novel ACSL4 interacting protein and its role in regulating ACSL4 degradation[J]. J Proteomics, 2020, 229:103926.
[20] Singh A B, Kan C F K, Kraemer F B, et al. Liver-specific knockdown of long-chain acyl-CoA synthetase 4 reveals its key role in VLDL-TG metabolism and phospholipid synthesis in mice fed a high-fat diet[J]. Am J Physiol Endocrinol Metab, 2019, 316(5):E880-E894.
[21] Stockwell B R, Friedmann Angeli J P, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease[J]. Cell, 2017, 171(2):273-285.
[22] Nelson J E, Wilson L, Brunt E M, et al. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease[J]. Hepatology, 2011, 53(2):448-457.
[23] Valenti L, Moscatiello S, Vanni E, et al. Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--A propensity score-adjusted observational study[J]. QJM, 2011, 104(2):141-149.
[24] Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis[J]. Cell Death Dis, 2019, 10(6):449.
[25] Qi J, Kim J W, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice[J]. Am J Pathol, 2020, 190(1):68-81.
[26] Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis[J]. Curr Gastroenterol Rep, 2003, 5(1):18-25.
[27] Tong J, Lan X T, Zhang Z, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis[J]. Acta Pharmacol Sin, 2023, 44(5):1014-1028.
[28] Duan J, Wang Z, Duan R, et al. Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice[J]. Hepatology, 2022, 75(1):140-153.
[29] Pavlova N N, Thompson C B. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23 (1):27-47.
[30] Ndiaye H, Liu J Y, Hall A, et al. Immunohistochemical staining reveals differential expression of ACSL3 and ACSL4 in hepatocellular carcinoma and hepatic gastrointestinal metastases[J]. Biosci Rep, 2020, 40(4):BSR20200219.
[31] Qin X, Zhang J, Lin Y, et al. Identification of MiR-211-5p as a tumor suppressor by targeting ACSL4 in Hepatocellular Carcinoma[J]. J Transl Med, 2020, 18(1):326.
[32] Chen J, Ding C, Chen Y, et al. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway[J]. Cancer Lett, 2021, 502:154-165.
[33] Chen J, Ding C, Chen Y, et al. ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis[J]. Oncogenesis, 2020, 9(4):42.
[34] Cui M, Xiao Z, Sun B, et al. Involvement of cholesterol in hepatitis B virus X protein-induced abnormal lipid metabolism of hepatoma cells via up-regulating miR-205-targeted ACSL4[J]. Biochem Biophys Res Commun, 2014, 445(3):651-655.
[35] Wang J, Wang Z, Yuan J, et al. The positive feedback between ACSL4 expression and O-GlcNAcylation contributes to the growth and survival of hepatocellular carcinoma[J]. Aging (Albany NY), 2020, 12(9):7786-7800.
[36] Xia H, Lee K W, Chen J, et al. Simultaneous silencing of ACSL4 and induction of GADD45B in hepatocellular carcinoma cells amplifies the synergistic therapeutic effect of aspirin and sorafenib[J]. Cell Death Discov, 2017, 3:17058.
[37] Li P, Zhang L, Guo Z, et al. Epimedium koreanum nakai-induced liver injury-A mechanistic study using untargeted metabolomics[J]. Front Pharmacol, 2022, 13:934057.
[38] Tu C, Xu Z, Tian L, et al. Multi-omics integration to reveal the mechanism of hepatotoxicity induced by dictamnine[J]. Front Cell Dev Biol, 2021, 9:700120.
[39] Pan Y, Tang P, Cao J, et al. Lipid peroxidation aggravates anti-tuberculosis drug-induced liver injury: evidence of ferroptosis induction[J]. Biochem Biophys Res Commun,2020, 533(4):1512-1518.
[40] Zhao W, Lei M, Li J, et al. Yes-associated protein inhibition ameliorates liver fibrosis and acute and chronic liver failure by decreasing ferroptosis and necroptosis[J]. Heliyon,2023, 9(4):e15075.
[41] Wei Y Y, Wang H R, Fan Y M, et al. Acute liver injury induced by carbon tetrachloride reversal by Gandankang aqueous extracts through nuclear factor erythroid 2-related factor 2 signaling pathway[J]. Ecotoxicol Environ Saf, 2023, 251:114527.
[42] Silva C M, Ferrari G D, Alberici L C, et al. Cellular and molecular effects of silymarin on the transdifferentiation processes of LX-2 cells and its connection with lipid metabolism[J]. Mol Cell Biochem, 2020, 468(1-2):129-142.
[43] Zhu L, Chen D, Zhu Y, et al. GPX4-regulated ferroptosis mediates S100-induced experimental autoimmune hepatitis associated with the Nrf2/HO-1 signaling pathway[J]. Oxid Med Cell Longev, 2021, 2021:6551069.
[44] Zou S, Sun H, Peng Y, et al. Mu-opioid receptor alleviated ferroptosis in hepatic ischemia-reperfusion injury via the HIF-1α/KCNQ1OT1 axis[J]. Am J Physiol Cell Physiol, 2023, 324(4):C927-C940.
[45] Chen L D, Wu R H, Huang Y Z, et al. The role of ferroptosis in chronic intermittent hypoxia-induced liver injury in rats[J]. Sleep Breath, 2020, 24(4):1767-1773.
[46] Xu Y, Denning K L, Lu Y. PPARα agonist WY-14,643 induces the PLA2/COX-2/ACOX1 pathway to enhance peroxisomal lipid metabolism and ameliorate alcoholic fatty liver in mice[J]. Biochem Biophys Res Commun, 2022, 613:47-52.
[47] Li S P, Li X Q, Chen X J, et al. Characterization and proteomic analyses of proinflammatory cytokines in a mouse model of liver transplant rejection[J]. Oxid Med Cell Longev, 2022, 2022:5188584. |
